A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorSeoul National University Hospital
About this trial
The incidence and prevalence of pulmonary disease due to Non-tuberculous mycobacteria (NTM) is increasing worldwide, and this trend has been confirmed in Korea. Treatment of NTM pulmonary disease is difficult and usually requires more than two years of long-term treatment, and the antibiotic regimens used in treatment vary. Therefore, it is difficult to track the natural history of patients with NTM pulmonary disease, to evaluate the treatment outcome, and to understand the effect of specific medicines on the outcome. Establishing a prospective registry of patients with NTM pulmonary disease is expected to accurately evaluate the progress, treatment modality, and treatment outcome of NTM pulmonary disease.
Eligibility criteria
Qualifiers
Clinical diagnosis of NTM pulmonary disease.
The causative agent of NTM pulmonary disease includes: M. avium complex, or M. abscessus subspecies abscessus, or M. abscessus subspecies massiliense, or M. kansasii.
Patients who starts new treatment (those who have previous history of treatment are eligible)
Disqualifiers
Patients who have been treated for more than 4 weeks.
The causative agent of NTM pulmonary disease is none of M. avium complex, M. abscessus subspecies abscessus, M. abscessus subspecies massiliense, or M. kansasii.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
Sponsors and collaborators
Seoul National University Hospital
Lead sponsor
Asan Medical Center
Collaborator
Samsung Medical Center
Collaborator
Pusan National University Hospital
Collaborator
Severance Hospital
Collaborator
Pusan National University Yangsan Hospital
Collaborator
Chonnam National University Hospital
Collaborator
Korean Institute of Tuberculosis
Collaborator
International Tuberculosis Research Center
Collaborator
Source ClinicalTrials.gov